CDC is ending RT-PCR testing in favor of multiplex rapid antigen test to distinguish Covid from Flu. See CDC notice below. What they are not telling us is that the RT-PCR test has very high false positives, inflating the numbers. The rapid antigen test is more accurate and gives results in minutes, so medical care decisions can be made ASAP. Labs will start transitioning before the Dec 31, 2021 cutoff so numbers will start to drop, just in time for 2022 election year. England has been using the rapid antigen test for over a year.
07/21/2021: Lab Alert: Changes to CDC RT-PCR for SARS-CoV-2 Testing Audience: Individuals Performing COVID-19 TestingLevel: Laboratory AlertAfter December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives. Visit the FDA website for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, visit this page.In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.Opt in to receive updates from the CDC Laboratory Outreach Communication System (LOCS).Online resources:• FAQ: CDC Distribution of COVID-19 Assays• Guidance for SARS-CoV-2 Point-of-Care Testing• Interim Guidance for SARS-CoV-2 Antigen Testing• Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19• Frequently Asked Questions about COVID-19 for Laboratories• Information for Laboratories about COVID-19• CDC COVID-19 Website• Clinical Laboratory COVID-19 Response Weekly Calls• CDC Laboratory Outreach Communication System (LOCS)If you have any questions, please contact us at LOCS@cdc.gov.Thank you,The Laboratory Outreach Communication SystemLaboratory Outreach Communication System (LOCS) | Division of Laboratory Systems (DLS)Center for Surveillance, Epidemiology, and Laboratory Services (CSELS)Centers for Disease Control and Prevention (CDC)LOCS@cdc.govwww.cdc.gov/csels/dls/locsPage last reviewed: July 19, 2021Content source: Division of Laboratory Systems (DLS)